A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Public ClinicalTrials.gov record NCT04776018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT04776018
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Takeda
- Industry
- Enrollment
- 27 participants
Conditions and interventions
Interventions
- Daratumumab and Hyaluronidase-fihj Drug
- Mezagitamab Drug
- TAK-981 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 19, 2021
- Primary completion
- Aug 1, 2023
- Completion
- Nov 8, 2023
- Last update posted
- Oct 1, 2024
2021 – 2023
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona - PPDS | Scottsdale | Arizona | 85259 | — |
| Mayo Clinic Jacksonville - PPDS | Jacksonville | Florida | 32224 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322-1013 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817 | — |
| Mayo Clinic - Cancer Center - Rochester - PPDS | Rochester | Minnesota | 55905 | — |
| Oncology Hematology West (Omaha) - USOR | Omaha | Nebraska | 68130 | — |
| Weill Cornell Medical Center | New York | New York | 10065 | — |
| TriHealth Cancer Institute | Cincinnati | Ohio | 45220 | — |
| Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Northeast Texas Cancer and Research Institute | Tyler | Texas | 75702 | — |
| Medical College of Wisconsin Cancer Center | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04776018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2024 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04776018 live on ClinicalTrials.gov.